Prothena Corporation plc (PRTA) - Total Liabilities
Based on the latest financial reports, Prothena Corporation plc (PRTA) has total liabilities worth $57.64 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PRTA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Prothena Corporation plc - Total Liabilities Trend (2010–2024)
This chart illustrates how Prothena Corporation plc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PRTA total assets.
Prothena Corporation plc Competitors by Total Liabilities
The table below lists competitors of Prothena Corporation plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Iteos Therapeutics Inc
NASDAQ:ITOS
|
USA | $129.28 Million |
|
Taiwan Chinsan Electronic Industrial Co Ltd
TWO:8042
|
Taiwan | NT$4.89 Billion |
|
Consolidated Water Co Ltd
NASDAQ:CWCO
|
USA | $31.03 Million |
|
Hankook Shell Oil
KO:002960
|
Korea | ₩111.05 Billion |
|
Tongqinglou Dining Co Ltd
SHG:605108
|
China | CN¥3.32 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥321.96 Million |
|
Hind Rectifiers Limited
NSE:HIRECT
|
India | Rs3.14 Billion |
|
PetroVietnam Transportation Corp
VN:PVT
|
Vietnam | ₫10.84 Trillion |
Liability Composition Analysis (2010–2024)
This chart breaks down Prothena Corporation plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See PRTA net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Prothena Corporation plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Prothena Corporation plc (2010–2024)
The table below shows the annual total liabilities of Prothena Corporation plc from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $60.18 Million | -55.43% |
| 2023-12-31 | $135.02 Million | -0.72% |
| 2022-12-31 | $135.99 Million | -5.11% |
| 2021-12-31 | $143.32 Million | -3.79% |
| 2020-12-31 | $148.97 Million | +1.79% |
| 2019-12-31 | $146.35 Million | -16.75% |
| 2018-12-31 | $175.80 Million | +97.22% |
| 2017-12-31 | $89.14 Million | -5.74% |
| 2016-12-31 | $94.57 Million | +284.96% |
| 2015-12-31 | $24.57 Million | +72.68% |
| 2014-12-31 | $14.23 Million | +55.66% |
| 2013-12-31 | $9.14 Million | +226.55% |
| 2012-12-31 | $2.80 Million | -72.16% |
| 2011-12-31 | $10.05 Million | +214.19% |
| 2010-12-31 | $3.20 Million | -- |
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson… Read more